Replies to post #76570 on Biotech Values

[DewDiligence]

did Boger state this before or after PROVE-2 came out?

Before and after.

because telaprevir and interferon without rib produces dramatic reductions in VL - way more than rib plus interferon - yet SVR in prove 2 for soc was better than telaprevir (minus rib). so it must follow that inhibition of relapse (and/or late rebound on treatment) is the primary moa by which rib acts to improve svr

I interpret Boger’s remark that ribavirin’s main contribution is on the “front end” to refer to the RVR rate, specifically, rather than the mean reduction in viral load.